Mario G. Giani-Pavez
Groningen, GR, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Zeb2os: A Noncoding Obstacle to Healing Hearts.
Journal: Circulation research
Published: February 26, 2026
Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy.
Journal: Cell
Published: April 14, 2025
Enhancing KLF15 activity in cardiomyocytes: a novel approach to prevent pathological reprogramming and fibrosis via nuclease-deficient dCas9VPR.
Journal: Signal transduction and targeted therapy
Published: December 10, 2024
mtDNA analysis using Mitopore.
Journal: Molecular therapy. Methods & clinical development
Published: September 14, 2023
Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?
Journal: Journal of internal medicine
Published: February 09, 2022
Recent Advances in Modeling Mitochondrial Cardiomyopathy Using Human Induced Pluripotent Stem Cells.
Recent Advances in Modeling Mitochondrial Cardiomyopathy Using Human Induced Pluripotent Stem Cells.
Journal: Frontiers in cell and developmental biology
Published: October 23, 2021
Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes.
Journal: International journal of molecular sciences
Published: September 28, 2021
Gain-of-function mutation in ubiquitin-ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues.
Journal: The Journal of clinical investigation
Published: July 22, 2021
ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIδ.
Journal: International journal of molecular sciences
Published: March 15, 2021
The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise.
Journal: Pflugers Archiv : European journal of physiology
Published: February 01, 2021
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Journal: European journal of heart failure
Published: December 19, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026